Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells After Haploidentical Stem Cell Transplantation
Overview
Affiliations
Addback of donor T cells following T cell-depleted stem cell transplantation (SCT) can accelerate immune reconstitution and be effective against relapsed malignancy. After haploidentical SCT, a high risk of graft-versus-host disease (GVHD) essentially precludes this option, unless the T cells are first depleted of alloreactive precursor cells. Even then, the risks of severe GVHD remain significant. To increase the safety of the approach and thereby permit administration of larger T cell doses, we used a suicide gene, inducible caspase 9 (iCasp9), to transduce allodepleted T cells, permitting their destruction should administration have adverse effects. We made a retroviral vector encoding iCasp9 and a selectable marker (truncated CD19). Even after allodepletion (using anti-CD25 immunotoxin), donor T cells could be efficiently transduced, expanded, and subsequently enriched by CD19 immunomagnetic selection to >90% purity. These engineered cells retained antiviral specificity and functionality, and contained a subset with regulatory phenotype and function. Activating iCasp9 with a small-molecule dimerizer rapidly produced >90% apoptosis. Although transgene expression was downregulated in quiescent T cells, iCasp9 remained an efficient suicide gene, as expression was rapidly upregulated in activated (alloreactive) T cells. We have demonstrated the clinical feasibility of this approach after haploidentical transplantation by scaling up production using clinical grade materials.
Acidic pH can attenuate immune killing through inactivation of perforin.
Hodel A, Rudd-Schmidt J, Noori T, Lupton C, Cheuk V, Trapani J EMBO Rep. 2025; 26(4):929-947.
PMID: 39789387 PMC: 11850619. DOI: 10.1038/s44319-024-00365-6.
Evolving strategies for addressing CAR T-cell toxicities.
Rankin A, Duncan B, Allen C, Silbert S, Shah N Cancer Metastasis Rev. 2024; 44(1):17.
PMID: 39674824 PMC: 11646216. DOI: 10.1007/s10555-024-10227-1.
Diaby M, Wu H, Gao B, Shi S, Wang B, Wang S Adv Sci (Weinh). 2024; 11(29):e2400969.
PMID: 38774947 PMC: 11304231. DOI: 10.1002/advs.202400969.
Fully closed cell sorter for immune cell therapy manufacturing.
Matsumoto M, Tashiro S, Ito T, Takahashi K, Hashimoto G, Kajihara J Mol Ther Methods Clin Dev. 2023; 30:367-376.
PMID: 37637381 PMC: 10457513. DOI: 10.1016/j.omtm.2023.07.012.
Amberger M, Grueso E, Ivics Z Int J Mol Sci. 2023; 24(12).
PMID: 37372948 PMC: 10298327. DOI: 10.3390/ijms24129799.